Psych CASC / OSCE · Psychopharmacology — ECT and neurostimulation
Explaining ECT and cognitive risk to a patient and partner (CASC)
CASC-style communication station: shared decision on acute ECT vs rTMS, honest cognitive risk counselling, consent elements, and relapse-prevention framing without stigma or false reassurance.
On this page & tools
Target exams
Station instructions (candidate)
You have 7 minutes. Explain why ECT is being recommended for severe treatment-resistant melancholic depression with high risk, what modern ECT involves (anaesthesia, not a horror scene), cognitive risks honestly, and how rTMS/iTBS differs in urgency and evidence role. Invite questions. Do not guarantee cure. Do not dismiss fears. Do not invent legal section numbers. Offer written information and a follow-up for consent formalities.[1][2][3][5][7]
Marking domains
Empathy and agenda setting; accurate plain-language explanation of indication and modern technique; honest memory risk counselling with mitigation (placement/pulse width); clear comparison with rTMS (outpatient, no anaesthetic, different evidence niche, not equivalent for this severity/urgency); discussion of common side effects and rare serious risks; continuation/relapse-prevention mention; collaborative plan and check-back.[1][2][3][4][5][6]
Model communication map
- Open: thank them; ask what they have heard about ECT; acknowledge fear without ridicule.[2]
- Why now: severe depression has not responded to two proper medicine trials; symptoms include high suicide risk features; ECT is among the most effective short-term treatments for this severity.[1][2]
- What happens: short general anaesthetic, muscle relaxant, brief controlled electrical stimulation that produces a short seizure in the brain while the body is protected; oxygen and monitoring; usually two or three times a week for a course individualised to response.[2][7]
- Memory — honest: temporary confusion after sessions; learning can be fuzzy during the course and usually improves; some people notice gaps in personal memories around the treatment period — we take that seriously, choose techniques that reduce that risk where safe (for example right-sided and ultrabrief approaches), and monitor.[3][4]
- "Magnet treatment" (rTMS): real option for many people with treatment-resistant depression who are medically stable outpatients; no anaesthetic; good trial evidence including shorter theta-burst sessions. For this current severity and risk profile, ECT is more appropriate acutely; rTMS can be discussed later if the clinical picture fits.[5]
- Aftercare: medicines and/or spaced continuation ECT to reduce relapse — finishing the acute course is not the end of the plan.[6]
- Close: questions, written info, consent process next steps, partner support, crisis contacts.[7]
Common fails
- Saying "ECT never affects memory" or "ECT always permanently destroys memory".[3]
- Describing unmodified historical ECT imagery as current practice.[2]
- Dismissing rTMS as fake or promising rTMS as identical to ECT for malignant-risk depression.[5]
- Omitting relapse-prevention after successful treatment.[6]
- Coercive language without exploring values, or abandoning recommendation when risk is high and capacity is intact but fear is based on myth alone (explore, correct, re-recommend).[7]
References
- [1]UK ECT Review Group Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis Lancet, 2003.PMID 12642045
- [2]Espinoza RT, Kellner CH Electroconvulsive Therapy N Engl J Med, 2022.PMID 35172057
- [3]Sackeim HA, Prudic J, Fuller R, et al. The cognitive effects of electroconvulsive therapy in community settings Neuropsychopharmacology, 2007.PMID 16936712
- [4]Sackeim HA, Prudic J, Nobler MS, et al. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy Brain Stimul, 2008.PMID 19756236
- [5]Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D) Lancet, 2018.PMID 29726344
- [6]Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: CORE Arch Gen Psychiatry, 2006.PMID 17146008
- [7]Weiss A, Hussain S, Ng B, et al. RANZCP professional practice guidelines for the administration of electroconvulsive therapy Aust N Z J Psychiatry, 2019.PMID 30966782